SCHEMBL3147320

SCHEMBL3147320

CC(C)c1ccccc1C(C)C(=O)NCC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 3/20 0.54
MME P08473 6/20 0.50
ALDH1A1 P00352 3/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 2/20 0.46
PTGS2 P35354 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
KMT2A Q03164 2/20 0.45
ECE1 P42892 2/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MEN1 O00255 1/20 0.45
BLM P54132 1/20 0.45
NPEPPS P55786 1/20 0.45
ITGB3 P05106 1/20 0.44
ITGB1 P05556 1/20 0.44
ITGAV P06756 1/20 0.44
ITGA5 P08648 1/20 0.44
LPAR1 Q92633 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3145729 0.81 ACE (0.52) ACEMMEALDH1A1MAPTLMNA
SCHEMBL6137585 0.81 MME (0.62) ACEMMEALDH1A1MAPTLMNA
SCHEMBL10698158 0.80 ACE (0.48) ACEMMEALDH1A1MAPTLMNA
SCHEMBL3147315 0.74 MME (0.51) ACEMMEALDH1A1MAPTLMNA
SCHEMBL4418617 0.74 CXCL8 (0.63) ALDH1A1KMT2AHPGDHSD17B10MEN1
SCHEMBL1343676 0.74 PTGS2 (0.50) ALDH1A1MAPTLMNAPTGS2KMT2A
Bicarbonate SCHEMBL9248270 0.73 GABRA1 (0.56) LMNAKMT2AHPGDBLM
SCHEMBL5282755 0.72 L3MBTL1 (0.47) MAPTLMNAKMT2AMEN1ITGB3
SCHEMBL21261672 0.72 ACE (0.78) ACEMMEALDH1A1MAPTKMT2A
SCHEMBL5540459 0.71 CYP3A4 (0.69) ACEMMEALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705050-B2 Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2010-04-27 US disclosed
EP-1255726-B1 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS DOMPE PHA R MA SPA RES & MFG (IT) 2009-11-11 EP disclosed
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2004-09-16 US disclosed
EP-1255726-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.P.A. (IT) 2002-11-13 EP disclosed
WO-2001058852-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.p.A. (IT) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils CXCL8, MMP8, CCR8 ACE 1844/4885MME 2941/4885ALDH1A1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.